ACET vs. ADMA, URI, FAST, GWW, WSO, WCC, AIT, AL, GATX, and MSM
Should you be buying Adicet Bio stock or one of its competitors? The main competitors of Adicet Bio include ADMA Biologics (ADMA), United Rentals (URI), Fastenal (FAST), W.W. Grainger (GWW), Watsco (WSO), WESCO International (WCC), Applied Industrial Technologies (AIT), Air Lease (AL), GATX (GATX), and MSC Industrial Direct (MSM).
Adicet Bio vs. Its Competitors
ADMA Biologics (NASDAQ:ADMA) and Adicet Bio (NASDAQ:ACET) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and earnings.
In the previous week, ADMA Biologics had 7 more articles in the media than Adicet Bio. MarketBeat recorded 10 mentions for ADMA Biologics and 3 mentions for Adicet Bio. ADMA Biologics' average media sentiment score of 1.59 beat Adicet Bio's score of 0.76 indicating that ADMA Biologics is being referred to more favorably in the media.
ADMA Biologics has higher revenue and earnings than Adicet Bio. Adicet Bio is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.
ADMA Biologics has a net margin of 44.06% compared to Adicet Bio's net margin of 0.00%. ADMA Biologics' return on equity of 41.01% beat Adicet Bio's return on equity.
ADMA Biologics has a beta of 0.54, meaning that its stock price is 46% less volatile than the S&P 500. Comparatively, Adicet Bio has a beta of 1.66, meaning that its stock price is 66% more volatile than the S&P 500.
ADMA Biologics presently has a consensus price target of $27.67, suggesting a potential upside of 60.85%. Adicet Bio has a consensus price target of $6.00, suggesting a potential upside of 716.99%. Given Adicet Bio's higher probable upside, analysts clearly believe Adicet Bio is more favorable than ADMA Biologics.
75.7% of ADMA Biologics shares are held by institutional investors. Comparatively, 83.9% of Adicet Bio shares are held by institutional investors. 3.7% of ADMA Biologics shares are held by insiders. Comparatively, 7.8% of Adicet Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Summary
ADMA Biologics beats Adicet Bio on 10 of the 15 factors compared between the two stocks.
Get Adicet Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACET and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ACET and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Adicet Bio Competitors List
Related Companies and Tools
This page (NASDAQ:ACET) was last updated on 9/3/2025 by MarketBeat.com Staff
